Immuneering (NASDAQ:IMRX) Raised to Hold at Wall Street Zen

Immuneering (NASDAQ:IMRX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th. Chardan Capital reissued a “buy” rating and issued a $20.00 target price on shares of Immuneering in a research report on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Immuneering presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Immuneering Trading Up 7.0%

IMRX stock opened at $5.33 on Friday. The stock’s 50 day simple moving average is $5.22 and its 200 day simple moving average is $6.08. Immuneering has a 12-month low of $1.10 and a 12-month high of $10.08. The stock has a market capitalization of $344.16 million, a PE ratio of -2.99 and a beta of 0.46.

Immuneering (NASDAQ:IMRX) last posted its earnings results on Friday, March 6th. The company reported ($0.18) EPS for the quarter. On average, research analysts predict that Immuneering will post -1.86 earnings per share for the current year.

Insider Buying and Selling at Immuneering

In other Immuneering news, Director Thomas J. Schall purchased 21,645 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were acquired at an average price of $4.67 per share, for a total transaction of $101,082.15. Following the purchase, the director directly owned 74,530 shares of the company’s stock, valued at $348,055.10. The trade was a 40.93% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Peter Feinberg acquired 20,000 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were acquired at an average cost of $4.35 per share, with a total value of $87,000.00. Following the transaction, the director owned 135,441 shares in the company, valued at approximately $589,168.35. This trade represents a 17.32% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 51,819 shares of company stock worth $234,472 in the last quarter. Corporate insiders own 22.90% of the company’s stock.

Institutional Trading of Immuneering

Several hedge funds have recently bought and sold shares of IMRX. Caitong International Asset Management Co. Ltd bought a new position in shares of Immuneering in the fourth quarter worth about $33,000. SummitTX Capital L.P. bought a new position in shares of Immuneering during the 4th quarter valued at approximately $69,000. 683 Capital Management LLC purchased a new stake in Immuneering in the 4th quarter worth approximately $992,000. Price T Rowe Associates Inc. MD increased its holdings in Immuneering by 10.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,993,958 shares of the company’s stock worth $13,121,000 after acquiring an additional 195,176 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in Immuneering during the 4th quarter worth approximately $607,000. Institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.